Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

IDU, prevention
Mo.(.14I8,Mo( I 125,Htt(1.1539,
Mo.C.16/9, Mo.( 46 1,MoC.462,
No.(1.464, Mu D111,/I K D I828,
No.D. 1949, No D2)2 1 A 125
No.D.361, Aol).366, I tth( 257,
Pob.1). I1338, Pub.1)1361, It ibCl). I111/,
Pub.). 14/0, OthC 420, f t311508.
10(11.629,1 0 31 666, l t C.16/I,
TI.C.686,10D.C)2 Il1t.D4990,
Tu.(. 204,lu 2'195,Itt 2149/7,
10(1.2503, Yu 31 250 1,10lu:(2506,
Tu,(.25 IS, itt 3 52 u.25t2 5,
bu.C 2527. Iti).251/ 1u31 2549,
101.2.553, Itt.N Iet 1,.C2058,
Iu.(1C.320, StE 32)4, lo C S/0,We.C.225,
We.(1.3534,W( (.13536, We (.3538.
We.(1.3539, VV. (13j 10 We.(1.354 I,
We.(1.3542 W (1.3543 We.(1.35-16,
We.(1.35,18 Wt 31 35 19 We.(.355 I,
We.(1.3552 Wt (13553 Wt (.3557,
We.(1.3559 VWet (.1560, We.(1.356 I,
We.(1.3562 We (1 3563 iWe.C.3564,
We.(1.3567 We.31 >69 VWe.(.357 I,
We.D.352,VWet 1336 VWe.D133774,
We.L).3799
IDU, prognosis
Mo.B.425, 1031 721VWe 33329,
We.B.411I,We.C IjI!
IDU, progression
MoB. I1258, Mu 8 I1345, Pub It I1407,
10.B.4270,Th.(1.220, 1 6.0.223, I It 31224,
TuB. 194, iu.(1.43 I, We.L3.31149,
We.B.31I53, We.C.3'I00, 5").0.31131
We.(1.3424, We.(1.34130
IDU, psychological
MoED. I858, MoD. I19,41,1 0..1111,
16.1951I59, O~.(.)4905, Iet.31.2513,
We.(1.35 70
IDU, SEE sexual behaviour
1431.2497, Iu.2533, Itt(_.7559,
We (.3538, We 31.35531
IDU, support
MolD. 1945, Mo. 1949, I Iii.47 14,
Th.D.51 93l.1.0.465,ti.C1.320,
We.(1.3543, Wo.31.3553, We.(.35 70,
We.(1.3571
IDU, testing
Mo.(1.2 10, Met.31.2 I5, Il e.C.460,
MoD. I1854,-101.4603,.15.0.1629,
We.(1.35 I 2,VVte.31..355 I, We.I3.3665
IDU, treatment
Mo.B. I1I62, Mo.B. I1I73,HoC.1I65 1,
MoD. I 802, T e.B.4 145, 10(1..4634,
lu.(1.2SOY, 33.2 527, Wo. 31 49,
We.C.342 1, We..115:36 I,'1.1).3(67,
We.D.37 I12
IDU, women
Mo.C 220, Met 3.27 1, Mu.311.450,
Mo.DI17/ I, Mo 119, No.31.19413,
31.8. I I ',10 (120311131 4508,
10(1.4640,(It [.232 l.It )1)56,
10.D1.5164,-1U.B2212 it( 14C:21,
Tu.(1.2.465, TO3 21318 lu.C 24/S.
lu.(1.2493,ltt31 2K)03,1.02501,
10(1.2531I. lt (12)32 itt (1251,
Tu.(C. 2653.lu( 2655 1u31 560,

10.8.421 7, ht.311203, F.C.)21I,1 h.(1.222,
Th.(.224,Th.(1.420,ITe.(.42 5, 10h.31.4368,

I I.(.4643,lTh.(1.466 I 10(1.4666,
-T (1.4674, 31.D.363,1.D.4990.
Th. D.5 I189, lo.A.2054, Tu.A.2078,
TuoB. I190,1[.8B.2 I180, lu. B.2206, Tu. B.22 15,
131.(.204, Tu.(.22 I, u.(1.2402,Tu.(1.2403,
10(1C.248 I Iee(.2492,lou.(.2496,
1.(.2'199, 10(1.2501,lu.(1.2502,
10(1C.2504, lu.(1.2505, u.(1.25O7,
10(1C.25 I I, lu.(1.25 I 3,Tu.(1.25 I15,
10(1.2 51I6, lu.(1.25 I7, Tu.(1.25 I8,
Tu.(1.251I9,-T.(.2520, Tu.(1.2522,
Tu.(.2526, T.(.2527,Tu.(1.2528,
10NC.2529, To.(1.253 I,Tu.(1.2536,
le.(.2537, 1.(.2539,Tou.(.2540,
Tu.(.254 I, 3u.(.2546,Tu.(.2548,
lu.(.2S49, lu.(1.2550,Tu.(1.255 I,
10u.31.2553, l(.2554,Tu.(1.2555,
Iu.(1.2556, ltu.(.2649,lo.(1.26S4,
Io.(1.320, 10(1.321I,Tu.(1.322,u.(1.57O,
Tu.D.2798, We.B.3 I149, We.B.3 166,
We.8.3206, We.B.3225, We.B.3359,
We.(1.2 I4, We.(1.2 I5, We.(1.225,
We.(1.226, We.(1.34 I, We.(1.34 IS,
We.(1.34 I16, We.(1.34 I17, We.(1.34 18,
We.(1.34 I19, We.(1.342, We.(1.3420,
We.(1.3422, We.(1.3424, We.(1.3454,
We.(1.3460, We.(1.3537, We.(1.3538,
We.(1.3542, We.(1.3548, We.(1.3553,
We.(1.3555, We.(1.3556, We.(1.3558,
We.(1.356 I, We.(1.3565, We.(1.3567,
We.(1.3569, We.(1.3570, We.D.2S4,
We.D.352, We.D.3655, We.D.3656,
We.[3.3657, We.D.3658, We.D.3659,
We.D.3664, We.D.3786, We.D.3799,
We.Li480
IL-I
We.A.3082, We.A.3084, We.A.3096
IL-2
PuO.B. l05 I,1 hA. I43,10.8.4 175,
1.8.4 I 83,10.8.4 184,Tu.A.2046,
Tu.A.38 I,Tu.A.382, We.A.3052,
We.A.3054, We.A.3056, We.A.3 101,
We.B.292, We.B.3 I123, We.B.3 197,
We.B.320 I
[L-2 receptor
Tu.B. 190, We.A.3052, We.A.3065
IL-6
No.A. 145, No.8.43 1, No.C1. 1548,
31.A.4060,Th.A.4065, We.A.3096
imaging, CT/MRI
No.8. I1268, 0tu.B.2263,lou.B.2295
imaging, other
No.8. 1272, Th.A.4076, Tu.B.2264
imaging, radiology
Mo.C1I662, Tu.B.2295
imaging, ultrasound
No.B. 1272,10.8. 172
immigration policy, SEE public policy
T.B.2363,leTu.D.2903,lou.D.2907,
We.D.3704
immune complexes
No.B. I 257,10.8.4 100, We.A.3048
immune serum globulin
(gamma globulin)
10.8.2318
immune therapy
T1h.8.4 100, 10h.8B.4 176,1Th.B.4 180,

Tu.A.2 105

immunoglobulin
Mo.B. 1221, No.8. 1283, No.8.43 1,
10.8.41 98,lh.8.4258,Iu.B. 183,
We.A,3020, We.A.3039, We.A.3049,
We.B.)163
immunoglobulin A
Mo.A. 152, No.8. I I/S. lu.B.2 I173,
We.A.30 12, We.A.30 16. VWe.A.3020,
We.A.3042, We.A.3049. VV.A.390,
We.A.39 I, We.B.) I167, We.B.) 179,
We.8.3303
immunoglobulin D
T0.A.4055
immunoglobulin E
No.8.431I,Th.A.40 I 8,lu.B.2333,
We.B.3324
immunoglobulin G
Mo.C1I528,lTh.A.4055, Iu.B.2305,
We.A.30 I19, We.A.3046, We.(1.3448
immunoglobulin M
No.8. 1289,lo.8.2305, We.A.3097
immunologic reconstitution
10.8. 172,Th.8B.4 I175,lou.A.270,
We.B.3200, We.B.3203
immunology
Mo.A.394, Mo.A.405, Mo.D. 1769,
MoD,3.1849, Pub.B. I1083,10h.8.4105.
10.8.4334,10(1. I 23,lu.A. 161,Tu.A.200 I,
Tu.A.284,lo.A.390, We.A. 143,
WeA.3030,We.A.3040. We.A.3047,
We.A.3057,We.A.3065, We.A.3067,
We.A.3075, We.B.3 I180, We.B.333 I.
We.(1.3465
immunomodulation
No.8.1304, Pob.A. 1025, Pub.B. 105 I,
0.8. 19 5,1T0.B.4 100,Th.8B.4174,
1h.8B.4 176,ITh.B.4 I180,10h.8.4 18 3,
10.8B.4 184, Tu.A.20 I19, Tu.A.270,
We.A.3034, We.A.3062, We.A.3068.
We.A.308 I, We.B.290, We.B.292,
We.B.3 I123, We.B.3 I14, We.B.3 197
immunopathology
Mo.A.394, No.B. 1297,Th.A. 161,
Th.A.408 I,10.A.4084,T0.A.4085,
1hB.4233,lo.A.2023, lo.A.2049,
loA,382,lo.B.2253. We.A. 101,
We.A.3029, We.A.3040, We.A.304 I,
We.A.3044, We.A.3048, We.A.305 I,
We.A.380, We.B.333 I
immunosuppression mechanism
lo.B.2304, We.B.3 199, We.B.3326
immunotherapy
Mo.A. 1045, Mo.A. 141, Mo.A.274,
Pub.B. I 032,10.8. 172,10.8. 173,10.8. 174,
10.8. 175,10h.8B.4 175,10h.8B.4178,
10.8.4 180,10.8.4 182,lth.B.433 I,
Tu.A.205 I,IoA.270,To.A.27 I,To.A.272,
To.A.382,To.B.52 I, We.A.3036,
We.A.308 I, We.A.405, We.B.290,
We.B.292,We.B.3 I182, We.B.) 195,
We.B.3 I196, We.B.3 I197, We.B.3203,
We.B.3323
immunotoxin
Io.A.272
inactivation
Mo.A. 1073
incidence

We.(1.222, We.(1.223, We.(1.224,
We.(1.225, We.(1.3445, We.(1.3488,

We.(1.3527, We.(1.56 I, We.(1.562,
We.D.3815
income
Mo.C. I1674, Pob.D. 1343, Pob.D. I1402,
10.13.253,10.13.4961 lo.B. I17 I,To.D.27S3,
lo.D.28 /4, We.D.3706, We.D.384 I
incubation
MoC. 1555, Mo.1. 1576. Mo.(1.322.
10.C.223,Tu.C.434,...435. We.B.3249.
We.(1.3400. We.(1.34 73
infection, biological properties
TuA. I14 I,Io.A.2023,Tu.B.2347
infection control
No.8. 1247, No.(1.1656. Mo.(1.570,
Pub.B. I 058,10.(1.4580,T0.(1.4732.
lu.A.2067,. Y..202, We.(1.3600.
We.D.3736
infection, primary
No.8.1331. No.8.1333, No.8. 1337,
Mo.C.5 /0,.Puo.C. I1I56, 10.A.4050.
To.A.20 I 6,To.A.2 I109, Tu.B.2 177.
lu.(1.2596, lo.C.2600. We.A.395,
We.8.3209, We.B.530
infectivity
Mo.A. 1036, Mo.A. 1080. Mo.A.270.
Ma.C57, Mo.C.572, Mo.(1.573.
10.A.385,10h.A.4036. buA. 1I, 4lo.A. I145,
Tu.A.2073,Tu.C.269 I, We.B.3383
influenza
To.A.385, We.B. Ill We.B. 113,
We. B.l114, We.B.3371
information systems
No.8. 1163,. MaC. 1400, Mo.C. 1405.
MoC. 1549. No.1.1760. Mo 13 1763.
No.. 1785, No.13.1922, No.13.1926,
No.13.235. No.13.252. No.13.253,
Pub.C. I1I57, Pub.C. 1 172, PoO.C. 1273,
Pob.C. I1276. Pub.D. 13 13, Pob.D. 1393.
Pob.D. 1395, Pub.D. I1494,10h.8.4 I43.
10(1.45 I 9,10(1.4539,.C(.4550.
10(1.4556.10(1C.4557.10(1C.4585.
10(1.4669,10(1C.4 779,10h.(.480S.
Th.(1.4843,Th.D.5 I I8,Io.(1.2 I2,
To.C.2 I14, lo.C.2S6O. lo.D.2879.
To.D.2925. lo.D.2939, We.C.3539,
We.D.3736, We.D.3758. We.D.3779.
We.D.3808, We.D.3809. We.D.3852,
We.D.3869, We.D.3884. We.D.3897,
We.D.3898
informed consent
MoC. I405,10.(1.4390,Io.B. I170.
lo.B.2 135, We.D.39 I15. We.[3.49 I
insemination
lTh.D.5099,lo.(1.26O I, We.C.35 14.
We.C.3528
insurance, SEE also health insurance
and life insurance
10(1.48 I 4,lth.D.372,Th.D.49SO.
10.1.4983. We.B.)154
integrase
Mo.A. 1019. Mo.A. 1020, No.A. 1045,
Mo.A. I1099, Th.A.380.10h.A.38,10h.8.403,
Io.A.264.lo.B.2282. lo.B.2283
integrated care model
No.B. 19 1,PPo.B. I1035,.PPo.B. I1039,
10.8. 19 1,10h..402.10.8.4 I I4,10.8.4 I1I7.
1h.C.4683,10.C.4738,Th.D.5 I160,

To.A.2003, Tu.A.20 I2,ITu.A.2037,
Iu.A.21 I IlouB.2 I 16,lu.B.22O3.

\O
Q)
0
u
C
LI)
0
C
Q)
C
0
C
0
CO
C
489